Top News

Road sign displaying the words Fast Track against a blue sky

RESEARCH

16 Jan 2026

FDA Fast Tracks Dual-Action MASH Drug: Is Momentum Back?

FDA grants two expedited reviews to a dual-action MASH drug, reviving interest in metabolic approaches without signaling a policy overhaul

Close-up of GLP-1 text under magnifying glass with obesity and diabetes terms

MARKET TRENDS

5 Feb 2026

Patients Take the Lead in US Metabolic Drug Pricing

PARTNERSHIPS

3 Feb 2026

AstraZeneca Brings AI In-House to Speed Drug Discovery

Latest News

A Weight-Loss Pill Without the Strings Attached

Close-up of Foundayo weight-loss medication tablet

INNOVATION

8 Apr 2026

Eli Lilly's once-daily GLP-1 pill Foundayo wins FDA approval, offering needle-free obesity care from $25 a month

Gloved hand placing blood sample vial into laboratory test tube rack

MARKET TRENDS

19 Feb 2026

Precision Medicine Rises as Biomarkers Drive Change

A biomarker surge is reshaping Europe’s healthcare market, driving consolidation, stricter regulation, and a push to align diagnostics wit...

PARTNERSHIPS

17 Feb 2026

Pfizer Steps Up Obesity Push With Metsera Deal

US drugmaker agrees multibillion-dollar acquisition to bolster metabolic pipeline and challenge leaders in weight-loss therapies

Insilico Medicine office entrance with AI branding and corporate signage

INSIGHTS

16 Feb 2026

AI Drugmaker Targets Obesity Beyond GLP-1

Insilico advances oral GIP candidate, signalling wider competition in weight-loss treatments

Gloved researcher examining pharmaceutical vial

REGULATORY

12 Feb 2026

FDA Tightens Grip on GLP-1 Copycats

FDA moves against copycat GLP-1 drugs, strengthening approved giants and reshaping the obesity market

Automated laboratory system screening drug compounds in petri dish

INNOVATION

11 Feb 2026

The New Front Line in AI Drug Discovery

Deep EigenMatics tops 2025 AI drug patents, speeding early discovery in obesity and diabetes research

PARTNERSHIPS

10 Feb 2026

AstraZeneca Bets on AI to Rethink Obesity Care

AstraZeneca and CSPC join forces, blending AI and long-acting dosing to speed new obesity and diabetes drugs across global markets

3 4 5...

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.